David T. Dicker

6.6k citations

125 papers · 5.1k indexed · h-index 40

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 12
- Cancer Genomics and Diagnostics 10
Oncology top 1%
- Cancer-related Molecular Pathways 41
- Cancer Cells and Metastasis 18
Molecular Biology top 2%
- Cell death mechanisms and regulation 42
- Cancer therapeutics and mechanisms 7
Biotechnology top 1%
- Cancer Research and Treatments 14
Cell Biology top 2%
Immunology
- interferon and immune responses 13

Co-authors: Wafik S. El‐Deiry Joshua E. Allen Zhaoyu Jin Wenge Wang Varun V. Prabhu Timothy F. Burns Nathan G. Dolloff Kimberly A. Scata
Cited by: Cancer Research Oncology Molecular Biology
Journals: Cancer Research (29 papers)Cancer Biology & Therapy (25 papers)Cell Cycle (14 papers)
Partner nations: United States India France

In The Last Decade

David T. Dicker

120 papers receiving 5.0k citations

Peers

Countries citing papers authored by David T. Dicker

Since Specialization

Citations

This map shows the geographic impact of David T. Dicker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Dicker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Dicker more than expected).

Fields of papers citing papers by David T. Dicker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Dicker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Dicker. The network helps show where David T. Dicker may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David T. Dicker, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David T. Dicker Line = papers co-authored together David T. Dicker links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90 Scientific Reports ·Shuai Zhao,Lanlan Zhou,David T. Dicker,Avital Lev,Shengliang Zhang,Eric A. Ross,Wafik S. El‐Deiry	2021	13
2	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer Molecular Cancer Research ·Avital Lev,Amriti R. Lulla,Brian C. Ross,Marie D. Ralff,Scott Perrie,David T. Dicker,Wafik S. El‐Deiry	2018	22
3	miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells Cancer Research ·Amriti R. Lulla,Michael Slifker,Yan Zhou,Avital Lev,Margret B. Einarson,David T. Dicker,Wafik S. El‐Deiry	2017	44
4	ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms Molecular Cancer Therapeutics ·Marie D. Ralff,C. Leah B. Kline,Tamara do Amaral Lopes,Jessica Wagner,Bora Lim,David T. Dicker,Varun V. Prabhu,Wolfgang Oster,Wafik S. El‐Deiry	2017	38
5	Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation Cancer Research ·Varun V. Prabhu,Bo Hong,Joshua E. Allen,Shengliang Zhang,Amriti R. Lulla,David T. Dicker,Wafik S. El‐Deiry	2016	49
6	Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC) Clinical Cancer Research ·Junaid Abdulghani,Ismaïl Kassau,Jean‐Nicolas Gallant,David T. Dicker,Hans van Herwaarde,Timothy K. Cooper,Jiangang Liao,Francis Harry Moore,Jing Liu,David Goldenberg,Niklas K. Finnberg,Wafik S. El‐Deiry	2016	35
7	The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death Journal of Biological Chemistry ·F. Safai Tehrani,David T. Dicker,Wafik S. El‐Deiry	2016	18
8	Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53 Cancer Research ·Shengliang Zhang,Lanlan Zhou,Bo Hong,A. Pieter J. van den Heuvel,Varun V. Prabhu,Noel A. Warfel,C. Leah B. Kline,David T. Dicker,Levy Kopelovich,Wafik S. El‐Deiry	2015	92
9	Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10 Cancer Research ·Joshua E. Allen,Varun V. Prabhu,Mala K. Talekar,A. Pieter J. van den Heuvel,Bora Lim,David T. Dicker,Jennifer L. Fritz,順正細井,Wafik S. El‐Deiry	2015	35
10	Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem–like Cells in an Akt/Foxo3a/TRAIL–Dependent Manner Cancer Research ·Varun V. Prabhu,Joshua E. Allen,David T. Dicker,Wafik S. El‐Deiry	2015	113
11	COX-2 Drives Metastatic Breast Cells from Brain Lesions into the Cerebrospinal Fluid and Systemic Circulation Cancer Research ·Sara Flamini,Akshal Patel,Varun V. Prabhu,David T. Dicker,Jonas M. Sheehan,Michael Glantz,Wafik S. El‐Deiry	2014	15
12	Prodigiosin Rescues Deficient p53 Signaling and Antitumor Effects via Upregulating p73 and Disrupting Its Interaction with Mutant p53 Cancer Research ·Bo Hong,Varun V. Prabhu,Shengliang Zhang,A. Pieter J. van den Heuvel,David T. Dicker,Levy Kopelovich,Wafik S. El‐Deiry	2013	69
13	Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes Molecular Cancer Therapeutics ·Joshua E. Allen,Roger Ferrini,David T. Dicker,Glenda Batzer,Abdelfateh Chourir,Daniela I. Oltean,Bing Lin,Mark W. Renshaw,Anke Kretz-Rommel,Wafik S. El‐Deiry	2012	25
14	Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9 Molecular Cancer Therapeutics ·Nathan G. Dolloff,Joshua E. Allen,David T. Dicker,Nicole A. Aqui,Dan T. Vogl,Jozef Malysz,Giampaolo Talamo,Wafik S. El‐Deiry	2012	12
15	Overcoming Hypoxia-Induced Apoptotic Resistance through Combinatorial Inhibition of GSK-3β and CDK1 Cancer Research ·Patrick A. Mayes,Nathan G. Dolloff,Colin J. Daniel,T.C. VanderMeulen,Lori S. Hart,Kageaki Kuribayashi,Joshua E. Allen,David Jee,Jay F. Dorsey,Yingqiu Y. Liu,David T. Dicker,J. Martin Brown,Emma E. Furth,Peter S. Klein,Rosalie C. Sears,Wafik S. El‐Deiry	2011	27
16	High-Resolution Imaging and Antitumor Effects of GFP+ Bone Marrow-Derived Cells Homing to Syngeneic Mouse Colon Tumors American Journal Of Pathology ·Niklas K. Finnberg,Lori S. Hart,Nathan G. Dolloff,Zachary B. Rodgers,David T. Dicker,Wafik S. El‐Deiry	2011	3
17	Cell Cycle–Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation Cancer Research ·John P. Plastaras,Seok-Hyun Kim,Yingqiu Y. Liu,David T. Dicker,Jay F. Dorsey,James E. McDonough,George J. Cerniglia,Ramji R. Rajendran,Anjali Gupta,Anil K. Rustgi,J. Alan Diehl,Charles D. Smith,Keith T. Flaherty,Wafik S. El‐Deiry	2007	118
18	Differentiation of vascular and non-vascular skin spectral signatures using in vivo hyperspectral radiometric imaging: Implications for monitoring angiogenesis Cancer Biology & Therapy ·Paul C. Tumeh,Jeremy M. Lerner,David T. Dicker,Wafik S. El‐Deiry	2007	3
19	Acridine derivatives activate p53 and induce tumor cell death through bax Cancer Biology & Therapy ·Wenge Wang,William C. Ho,David T. Dicker,Arslan AKGÜNLÜ,Jeffrey D. Winkler,Ronen Marmorstein,Wafik S. El‐Deiry	2005	68
20	Chemokine Receptors and the Molecular Basis for Human Immunodeficiency Virus Type 1 Entry into Peripheral Hematopoietic Stem Cells and Their Progeny The Journal of Infectious Diseases ·Érica Brito de Santana,中津楢男,Geethanjali Dornadula,David T. Dicker,James A. Hoxie,Stephen C. Peiper,Roger J. Pomerantz,Lingxun Duan	1998	9

About David T. Dicker

David T. Dicker is a scholar working on Oncology, Cancer Research, Biotechnology, Molecular Biology and Applied Microbiology and Biotechnology, having authored 125 papers that have together received 5.1k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (42 papers), Cancer-related Molecular Pathways (41 papers), Cancer Cells and Metastasis (18 papers), Cancer Research and Treatments (14 papers), interferon and immune responses (13 papers), Cancer, Hypoxia, and Metabolism (12 papers), Cancer Genomics and Diagnostics (10 papers) and Cancer therapeutics and mechanisms (7 papers). The work is most often cited by research in Cancer Research (1.2k citations), Oncology (1.9k citations), Molecular Biology (3.5k citations), Biotechnology (382 citations) and Cell Biology (490 citations). David T. Dicker has collaborated with scholars based in United States, India and France. Frequent co-authors include Wafik S. El‐Deiry, Joshua E. Allen, Zhaoyu Jin, Wenge Wang, Varun V. Prabhu, Timothy F. Burns, Nathan G. Dolloff, Kimberly A. Scata, E. Robert McDonald and M. Ricci. Their work appears in journals such as Cancer Research, Cancer Biology & Therapy, Cell Cycle, Journal of Biological Chemistry and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact